Meitav Dash Investments LTD Salarius Pharmaceuticals, Inc. Transaction History

Meitav Dash Investments LTD

  • $5.8 Billion
  • Q3 2024

Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2021

Feb 08, 2022
SELL
$0.49 - $1.01 $25,480 - $52,520
-52,000 Closed
0 $0
Q1 2021

May 06, 2021
BUY
$1.0 - $3.0 $52,000 - $156,000
52,000 New
52,000 $77,000

About Salarius Pharmaceuticals, Inc.

SLRX Quotes by TradingView
  • Ticker SLRX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 2,244,650
  • Market Cap $3.48M
  • Description
  • Salarius Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on developing epigenetic-based cancer treatments. Its lead candidate is Seclidemstat (SP-2577), a small molecular inhibitor which is in Phase I/II clinical trial for the treatment of advanced solid tumors, as well as Ewing sarcoma. The company also offers SP-3164, a ...
More about SLRX
Track This Portfolio

Track Meitav Dash Investments LTD Portfolio

Follow Meitav Dash Investments LTD and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Meitav Dash Investments LTD, based on Form 13F filings with the SEC.

News

Stay updated on Meitav Dash Investments LTD with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email